About the new and improved Hot Tort Report
Being industry experts, we pride ourselves on keeping our finger on the pulse of all things Multi District Litigation. This predominantly consists of providing our subscribers with competitive insights into where the money is being spent in hopes of informing your blueprint for advertising strategies and lead generation. These cases can be highly lucrative, but are difficult to acquire, requiring significant investment and patience to secure high-value cases.
We’ve been working hard on an algorithm to deliver more than just monthly TV spends and are proud to announce that we are ready to unveil our HTR 2.0.
This new list offers an overview of dollars spent across TV, Meta, PPC, and more, assigning a score to each tort based on what we, as leaders in the law firm advertising space, are witnessing across these various platforms.
The Hot Tort Report:
November 2025
The Hottest Trends in Mass Tort Marketing: November 2025
Birth Control Injections
Featured Tort
Subscribe to the Hot Tort Report
Mass Tort Marketing News
Published: November, 2025. Advertising spend from multiple sources for a recent 30 day period.
If you have any questions, please contact us at national@whitehardt.com
#1 Birth Control Injections
The Birth Control Injections tort stayed in the lead this month, rising 0.7 points overall. WHii cooled off, but Meta skyrocketed to hit a perfect 5.0. TV and PPC held steady, showing that this campaign’s strength is now solidly anchored in social engagement.
With steady national coverage and ad interest shifting toward Meta, this tort continues to command attention both online and in the courtroom, making it the clear front-runner heading into November.
CPA: $1,153
CPL: $680
For common criteria, please contact us.
#2 Paraquat
Paraquat slipped half a point this month but held onto the number two spot. WHii rose slightly while TV dipped just a touch and PPC dropped a full point. Meta stayed locked at 5.0, keeping this tort firmly in the digital spotlight even as overall activity cooled slightly.
In the courtroom, the stay remains in effect until January 2026 as settlement discussions continue to unfold. The dip in ad momentum likely reflects that pause, but with settlements still on the horizon, this tort remains a high-stakes player heading into the new year.
CPA: $711
CPL: $320
Common Criteria: Diagnosis of Parkinson’s Disease or experiencing Parkinson’s-like symptoms after exposure to Paraquat.
#3 Takata Airbag Recall
This tort surged in October, jumping up from 6th position to take the number three spot. WHii climbed, Meta rose significantly, and both TV and PPC held steady, showing renewed attention as key deadlines approach.
The final claim submission periods for Toyota and BMW vehicles are closing fast, driving a late-season push in awareness. With TV still leading the charge and digital spend on the rise, firms are moving fast to capture last-minute claims before time runs out.
For metrics such as CPA, CPL, and common criteria, please contact us.
#4 Rideshare Assault
Rideshare Assault ad scores dipped slightly this month. WHii climbed by 0.6 for this tort, while TV spend dropped 1.2 for an overall decrease. With TV now at zero, this tort’s presence remains fueled by strong digital engagement, especially on Meta.
Legally, the landscape is expanding. A motion filed in October seeks to consolidate Lyft sexual assault lawsuits into federal multidistrict litigation, mirroring the existing Uber MDL that now includes thousands of cases. Lawyers estimate “hundreds or thousands” of Lyft suits could follow.
For metrics such as CPA, CPL, and common criteria, please contact us.
#5 Roundup®
Roundup® climbed 0.8 points this month, powered by a strong Meta boost while other channels held steady. WHii and PPC stayed consistent, and TV remained off, with most firms sticking with digital to drive visibility.
In early October, the Missouri Supreme Court rejected Bayer’s appeal of a $611 million verdict, leaving the massive judgment intact. Bayer has hinted at taking its fight to the U.S. Supreme Court but still faces tens of thousands of pending claims.
CPA: $1,238
CPL: $743
For common criteria, please contact us.
#6 Diabetes Meds for Weight Loss
The Diabetes Meds for Weight Loss mass tort saw modest growth this month overall. PPC activity doubled, suggesting advertisers are leaning harder into search, even as WHii and Meta dipped slightly.
In court, Judge Karen Spencer Marston issued Case Management Order No. 27, setting formal procedures for short-form complaints. This step marks a key phase in organizing the thousands of Ozempic®, Wegovy®, and Mounjaro® claims now centralized in federal court. For firms, it’s a sign that the litigation is moving into a structured, high-volume phase, and attention on these weight loss drugs isn’t slowing down.
CPA: $91 – $463
CPL: $68 – $347
Common Criteria: Took a prescription diabetes drug for weight loss (e.g. Ozempic®, Mounjaro®), discontinued use of the drug, and experienced one or more gastrointestinal disorders at least 30 days after your first dose.
#7 Infant Formula
Infant Formula climbed two points this month, breaking into the top 10 after a period of quiet. Claims over toxic metals and premature birth injuries remain active in both state and federal court. As ongoing discovery continues to uncover internal company documents, interest from plaintiffs’ firms has reignited, hinting that this tort could see renewed traction heading into the year’s end.
For metrics such as CPA, CPL, and common criteria, please contact us.
#8 Dupixent®
Dupixent® makes its debut in the Hot Tort Report this month as lawsuits begin to consolidate around claims that the eczema and asthma drug may trigger T-cell lymphoma and related cancers. WHii and PPC are showing early traction as firms test the waters in this emerging mass tort space.
The first case management conference for the Dupixent® litigation recently took place, setting the tone for what could become a major pharmaceutical MDL. Plaintiffs allege that Sanofi and Regeneron failed to warn users about potential cancer risks, while additional wrongful death suits continue to be filed. As awareness spreads and evidence mounts, Dupixent® could climb quickly in both legal and advertising momentum heading into 2026.
If your firm is testing early campaigns or exploring entry into this tort, now’s the time to get in touch. We can help you identify where the ad traction is strongest.
For metrics such as CPA, CPL, and common criteria, please contact us.
#9 Social Media Addiction
Social Media Addiction tort advertisement climbed back up the rankings this month, driven by a strong surge in WHii activity and a notable lift in Meta engagement. PPC spending slipped, but the tort’s overall trajectory continues upward as public awareness and advertiser interest intensify.
The first bellwether trials have been rescheduled, with the initial California case now set to begin in January 2026. The delay follows new evidence linking social media harm to incidents of sexual predation. With momentum building in both the courtroom and ad channels, this tort is poised to stay on every firm’s radar heading into next year.
Planning for next year’s Social Media Addiction trials? Reach out. We’re tracking engagement shifts in real time.
For metrics such as CPA, CPL, and common criteria, please contact us.
#10 Hernia Mesh
Hernia Mesh reentered the top ten this month, buoyed by gains across most ad channels and a noticeable rise in WHii activity. Meta spending also climbed, helping offset a small dip in TV investment. The tort’s modest but steady growth suggests firms are reigniting campaigns ahead of potential movement in ongoing settlement discussions.
On the legal side, the hernia mesh MDL remains active, with thousands of cases still pending after years of litigation involving multiple manufacturers, including C.R. Bard, Atrium, and Ethicon. For now, hernia mesh is showing renewed advertiser confidence and holding steady as one of the most enduring and reliable torts in the landscape.
Common Criteria: Hernia mesh surgery from 2000—current; suffered from one of the following: Perforation, Bowel Obstruction, Mesh Erosion, Mesh Contraction, Torn Mesh, Sepsis/Infection, Granuloma, Adhesion, Dehiscence that resulted in a removal/repair, scheduled or future.
For metrics such as CPA and CPL, please contact us.
Mesothelioma Lawsuit Leads
You may be noticing a tort missing from our new report. While Mesothelioma continues to dominate the competition when it comes to spend levels, Whitehardt finds that this tort is its own niche animal. These cases can be extremely fruitful, but hard to come by, requiring a high buy-in to get in the game and patience when landing that ringer of a case. We believe that meso will remain a constant for some time, but in regards to many of the other drugs and devices we focus on in this monthly report, we’ve decided to move it to its own category. If you are interested in hearing the latest news on meso or how Whitehardt may be currently seeking these cases, you can contact us here.
Whitehardt will continue to track meso spending from month to month, so if you are interested in ongoing meso spending, please reach out to us directly. Going forward, we will be excluding meso from these mass tort marketing reports.
